ESR1 and breast carcinoma: Several studies have shown that endocrine resistance mechanisms depend on alterations of cell cycle regulators, which led to the development of cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) for ER+ advanced breast cancer (3–6).